[144] RECURSION PHARMACEUTICALS, INC. SEC Filing

Rhea-AI Filing Summary

Recursion Pharmaceuticals, Inc. (RXRX) filed a Form 144 notice reporting a proposed sale of 100,000 Class A shares through Fidelity Brokerage, with an aggregate market value of $604,000 and an approximate sale date of 10/10/2025 on NASDAQ. The filing shows these shares were originally acquired as Founders Shares on 09/01/2016 and were issued as compensation.

The filing also discloses multiple recent sales by related parties during the past three months: combined transactions on 08/11/2025 and later dates totaling at least 978,875 Class A shares with gross proceeds shown (for example, a single sale of 500,000 shares on 08/11/2025 for $2,640,000). The notice includes the seller representations required under Rule 144 and the usual signature attestation about absence of undisclosed material adverse information.

Positive

• Proper Rule 144 disclosure filed showing broker, amount, and planned sale date
• Shares originated as founders' compensation on 09/01/2016, documenting acquisition history

Negative

• Large recent insider sales reported in the past three months (e.g., 500,000 shares sold on 08/11/2025 for $2,640,000) which may increase share supply
• Additional planned sale of 100,000 shares on 10/10/2025 could further reduce insider ownership near-term

Insights

Insider Transactions Specialist

TL;DR: A founder-originated block of 100,000 shares is slated for sale, amid multiple large insider sales this quarter.

The filing identifies 100,000 Class A shares acquired as founders' shares on 09/01/2016 and listed for proposed sale with a reported market value of $604,000 on 10/10/2025. The mechanics follow Rule 144 disclosure: broker, amount, and intended sale date are provided.

Recent reported sales by related parties show substantial insider liquidity: for example, 500,000 shares sold on 08/11/2025 for $2,640,000. That pattern increases share supply in the market near-term and is a concrete item to monitor over the next weeks for price pressure and insider ownership shifts.

Corporate Governance Analyst

TL;DR: The transaction is routine Rule 144 disclosure but signals near-term insider exits that investors may note.

The notice confirms the securities were issued as compensation and were acquired in 2016, which supports their eligibility under resale rules. The form includes the standard attestation that the seller is unaware of undisclosed material adverse information.

Material items to watch over the next month include whether the 10/10/2025 sale occurs and any additional Form 4/Form 144 filings that would quantify remaining insider holdings. Changes in insider ownership can affect governance perceptions; those changes are directly traceable to the disclosed sale dates and amounts.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	100000	604000.00	427312960	10/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	09/01/2016	Founders Shares	Issuer			100000	09/01/2016	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christopher C. Gibson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	08/11/2025	500000	2640000.00
Gibson Family Trust 41 S Rio Grande Street Salt Lake City UT 84101	Class A	08/11/2025	17875	94380.00
Lahwran-3 Llc 41 S Rio Grande Street Salt Lake City UT 84101	Class A	08/11/2025	100000	528000.00
Christopher C. Gibson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	08/26/2025	100000	484000.00
Christopher C. Gibson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	09/10/2025	100000	471000.00
Christopher C. Gibson 41 S Rio Grande Street Salt Lake City UT 84101	Class A	09/25/2025	100000	476000.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the RXRX Form 144 disclose?

It discloses a proposed sale of 100,000 Class A shares (market value $604,000) through Fidelity with an approximate sale date of 10/10/2025.

Who originally acquired the shares being sold in the RXRX filing?

The shares were acquired as Founders Shares on 09/01/2016 and were issued as compensation.

Have insiders sold RXRX shares recently?

Yes. The filing lists multiple sales in the past three months, including 500,000 shares on 08/11/2025 for $2,640,000 and other sales totaling at least 978,875 shares.

On which exchange will the shares be sold?

The proposed sale is reported to occur on NASDAQ.

Does the filing state any undisclosed material information?

By signing, the seller represents they do not know any undisclosed material adverse information regarding the issuer.